Navigation Links
Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody
Date:10/2/2008

t of cancer through its affinity for a novel target, lactadherin. Lactadherin is an extracellular matrix protein that is released by numerous types of tumor cells, including most breast cancers, ovarian cancers and prostate cancer. Lactadherin has a critical role in promoting the growth of new blood vessels to support tumor growth through the activation of VEGF-mediated angiogenesis. The target lactadherin and Angiolix are supported and protected by granted patents.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
(Date:8/29/2014)... -- Pixcelldata, the innovative Irish developer of ... major new deal with Dutch based eX-Path, global providers ... Marius Nap . The announcement was ... Pathology which is taking placing between August 30th and ... where Pixcelldata will demonstrate its innovative solution. ...
(Date:8/28/2014)...  Rigrodsky & Long, P.A.: , Do you, ... LCI )? , Did you purchase your shares before ... 2014, inclusive? , Did you lose money in your ... to discuss your rights? Rigrodsky & ... Timothy J. MacFall , announces that a complaint has been filed ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
(Date:8/30/2014)... As the economy continues to recover ... style bathrooms and in-home fitness centers, the North ... in interest not only in designing and installing saunas ... benefits of sauna. Through working with manufacturers across ... Sauna Society provides a strong knowledge base of Finnish ...
(Date:8/30/2014)... 2014 UWDress.com, a distinguished wedding dress supplier, ... first range of fashionable outfits. Recently, the company has unveiled ... As an autumn special offer, all these brand new products ... , “We are excited to unveil the new and ... high quality products are available at low prices now. The ...
(Date:8/30/2014)... 2014 Recently, Skmen.com, a well-known clothing ... casual dresses . Before the middle of September, all ... discounted price, from 15 to 30 percent off. ... long casual outfits are carefully made and come with ... for the wearers. Skmen.com is popular for its fashionable, ...
(Date:8/30/2014)... Patients suffering from vitiligo can now discover a ... published by Daily Gossip. , Vitiligo is a ... no wonder that numerous sufferers search for an alternative ... one of the most appreciated such methods at the ... the spread of this disorder immediately, while completely curing ...
(Date:8/30/2014)... 30, 2014 The term nutraceuticals ... Pharameuticals. Nutraceuticals is a source of healthy-dietary supplements ... natural food sources. Nutraceutical ingredients have certain curative ... human body. Nutraceutical health products include factors such ... and more. Although nature is the most bountiful ...
Breaking Medicine News(10 mins):Health News:As Interest in Saunas Increases, the North American Sauna Society Increases Outreach to Provide Education on History, Design, and Culture 2Health News:UWDress.com’s Beautiful Collection Of “Flowy Bridesmaid Dresses” Released 2Health News:Huge Deals On 2014 Long Casual Dresses Unveiled By Skmen.com 2Health News:Natural Vitiligo Treatment Review Exposes Fast Method for Skin Repigmentation 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4
... SHENZHEN, China, Feb. 13 /PRNewswire-Asia/ -- Winner Medical Group Inc.,(OTC ... financial results for the first quarter ended December 31,2008. The ... with,the United States Securities and Exchange Commission. , , ... Total net sales revenue increased by 33.14% over the first ...
... the University of Brighton Medical School has chosen a Mecmesin MultiTest ... orthopaedic prosthesis for shoulder reconstruction. , ... Slinfold, West ... orthopaedic surgeon at the University of Brighton Medical School has chosen ...
... share most of their genes, including 70 percent of ... remarkable evolutionary conservation, researchers at the Salk Institute for ... model for an innovative study of gliomas, the most ... disease but we still know very little about the ...
... 44%, researchers say , , THURSDAY, Feb. 12 (HealthDay News) ... much as a 44 percent increased risk of developing ... has established a connection between smoking and increased risk ... the largest review to date showing a link between ...
... Feb. 12 Biotel Inc.,(OTC Bulletin Board: BTEL) announced ... net earnings of $289,000, or $0.10 per diluted share,on ... $206,000, or $0.07,per diluted share, on revenues of $2,859,000 ... months ended December 31, 2008, Biotel had net earnings ...
... The Pennsylvania Department of Health has reviewed and ... Hospital in Brownsville, Fayette County, which ceased operations ... have been relocated to other facilities. All hospital ... work, assisted with the patient transfer.Local ambulances and ...
Cached Medicine News:Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 2Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 3Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 4Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 5Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 6Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 7Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 8Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 9Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 10Health News:Force Tester Shoulders The Burden 2Health News:Fruit flies soar as lab model, drug screen for the deadliest of human brain cancers 2Health News:Fruit flies soar as lab model, drug screen for the deadliest of human brain cancers 3Health News:Secondhand Smoke Linked to Dementia 2Health News:Biotel Announces Profitable Second Quarter Ended December 31, 2008 2
... is based on SIREMOBIL Iso-C, the first ... the intra-operative 3D-Mode, the 3D-dataset is immediately ... orbital movement. This allows the surgeon to ... during the procedure. This 3D capability is ...
... Humphrey Field Analyzer II-i series is a ... the patient's visual field. ,By using SITA, ... is reduced by up to 70%. ,A ... ergonomic design to increase patient comfort while ...
... an innovative device designed to be a ... abdominal aortic aneurysms (AAA). It is constructed ... an outer self-expanding Nitinol support structure to ... The function of the endoprosthesis is to ...
... a cast from an arm or leg can ... cut or burned by the cast saw blade. ... remove any cast with confidence. This innovative, cut-resistant ... burns from the cast saw and can be ...
Medicine Products: